|
[1]
|
Klöppel, G. (2017) Neuroendocrine Neoplasms: Dichotomy, Origin and Classifications. Visceral Medicine, 33, 324-330. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Pan, W.-X., Zhang, X.-M., Hao, S.-L., et al. (2023) Progress in Immuno-therapy for Neuroendocrine Neoplasm of the Digestive System. World Journal of Gastroenterology, 29, 4174-4185. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Singh, S., Asa, S.L., Dey, C., et al. (2016) Diagnosis and Manage-ment of Gastrointestinal Neuroendocrine Tumors: An Evidence-Based Canadian Consensus. Cancer Treatment Reviews, 47, 32-45. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Ambrosini, V., Kunikowska, J., Baudin, E., et al. (2021) Consen-sus on Molecular Imaging and Theranostics in Neuroendocrine Neoplasms. European Journal of Cancer, 146, 56-73. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
高雨菡, 王萱, 薛华丹. 影像学在神经内分泌肿瘤合并肝转移患者早期治疗评价中的作用: 从解剖学到功能学[J]. 中国医学科学院学报, 2021, 43(6): 956-961.
|
|
[6]
|
Mete, O. and Wenig, B.M. (2022) Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Overview of the 2022 WHO Classification of Head and Neck Neuroendocrine Neoplasms. Head and Neck Pa-thology, 16, 123-142. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Duan, K. and Mete, O. (2016) Algorithmic Approach to Neuroendocrine Tumors in Targeted Biopsies: Practical Applications of Immunohistochemical Markers. Cancer Cytopathology, 124, 871-884. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Yao, J.C., Hassan, M., Phan, A., et al. (2008) One Hundred Years after “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States. Journal of Clinical Oncology, 26, 3063-3072. [Google Scholar] [CrossRef]
|
|
[9]
|
La Rosa, S. and Uccella, S. (2020) Classification of Neuroendo-crine Neoplasms: Lights and Shadows. Reviews in Endocrine and Metabolic Disorders, 22, 527-538. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Cui, J., Zhang, Y., Ren, X., et al. (2021) TBX1 Functions as a Tumor Activator in Prostate Cancer by Promoting Ribosome RNA Gene Transcription. Frontiers in Oncology, 10. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
徐建明, 梁后杰, 秦叔逵, 等. 中国胃肠胰神经内分泌肿瘤专家共识(2016年版) [J]. 临床肿瘤学杂志, 2016, 21(10): 927-946.
|
|
[12]
|
Janson, E.T., Holmberg. L., Stridsberg. M., et al. (1997) Carcinoid Tumors: Analysis of Prognostic Factors and Survival in 301 Patients from a Referral Center. Annals of Oncology, 8, 685-690. [Google Scholar] [CrossRef]
|
|
[13]
|
Jensen, K.H., Hilsted, L., Jensen, C., et al. (2012) Chromogranin A is a Sensitive Marker of Progression or Regression in Ileo-Cecal Neuroendocrine Tumors. Scandinavian Journal of Gastroenterology, 48, 70-77. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Welin, S., Stridsberg, M., Cunningham, J., et al. (2009) Ele-vated Plasma Chromogranin A Is the First Indication of Recurrence in Radically Operated Midgut Carcinoid Tumors. Neuroendocrinology, 89, 302-307. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Arnold, R., Wilke, A., Rinke, A., et al. (2008) Plasma Chromogranin A as Marker for Survival in Patients with Metastatic Endocrine Gastroenteropancreatic Tumors. Clinical Gastroenterology and Hepatology, 6, 820-827. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Singh, S., Granberg, D., Wolin, E., et al. (2016) Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From. JCO Global Oncology, 3, 43-53. [Google Scholar] [CrossRef]
|